Skip to content

Study for Newly Diagnosed Extra-Cranial Malignant Rhabdoid Tumor(eMRT-2025)

Study for Newly Diagnosed Extra-Cranial Malignant Rhabdoid Tumor(eMRT-2025)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108069
Enrollment
Unknown
Registered
2025-08-25
Start date
2025-08-31
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracranial Malignant Rhabdoid Tumor

Interventions

Low-Risk Group/High-Risk Group:NA

Sponsors

Children's Hospital of Nanjing Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Patients must meet all of the following conditions: 1. Age at onset = 60 for patients = 60 for patients >= 16 years of age. 4. Life expectancy of at least 12 weeks. 5. Tumor of non-central nervous system origin (extra-cranial). 6. Voluntary participation of the patient or/and their legal guardian(s), with written informed consent obtained. 7. Newly diagnosed cases (previously untreated).

Exclusion criteria

Exclusion criteria: Participants will be excluded from the study if they meet any of the following criteria: 1. The research participant or their legal guardian(s) is unable or unwilling to provide written informed consent. 2. Presence of a severe congenital anomaly that is potentially life-threatening. 3. The investigator determines that the patient has other severe comorbidities which preclude the ability to undergo chemotherapy or receive anti-angiogenic therapy.

Design outcomes

Primary

MeasureTime frame
Overall Survival, OS;Event-Free Survival, EFS ;

Secondary

MeasureTime frame
Adverse Event, AE ;

Countries

China

Contacts

Public ContactLi Zhou

Children’s Hospital of Nanjing Medical University

zhoulinjey@163.com+86 189 5176 9722

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026